People in boardroom

Empowering dealmakers,
in service of patients.

Leadership

Matt Jewkes

co-founder and cto

Matthew Jewkes has led at the forefront of multiple significant transitions in software, from introduction of the iPhone to advanced cryptographic methods, and now the rapidly emerging capabilities of Artificial Intelligence (AI) technologies.

Matthew oversees the development of MotionHall's technology, including the Model and Platform. Since inception in 2015, Matt has guided the development of a comprehensive digital twin of the global biopharmaceutical industry known as the MotionHall Model. This model leverages terabytes of proprietary industry data, massively indexed public data sets, and works on proprietary deep learning neural networks as well as other computational methodologies.

Matthew is also responsible for the creation and development of the Platform, including the specific deal enablement workflows and decision support tools available to MotionHall's membership.

Matt is an advocate for corporate social responsibility, customer success and employee success. Within MotionHall, he is a champion for the benefit of our members and the patients they serve. He has taken a strong stand against non-compete agreements which restrict employees' basic freedom to change jobs, and lead in equity education and options terms that protect teammates including a 10-year exercise period.

Matt studied Computer Science at Dalhousie University.

Rod Ferguson

board of directors

Dr. Rod Ferguson participates as an advisor, board member, mentor and investor at MotionHall. One of few senior dealmakers who has experienced strategic transactions from all sides of the table, Rod is able to comment on the complexities of transactions and their stakeholders from the perspective of a biotech, pharmaceutical company, venture investor and investment banker. A respected industry name, Rod has led some of the most widely recognized pharmaceutical licensing deals in the world including Genentech's in-licensing of Rituxan and auction of Herceptin.

Rod is the Managing Director of Panorama Capital, a venture capital firm which spun off from J.P. Morgan Partners (JPMP) in July 2006, where he oversees the firm's life sciences investments. He joined JPMP as a Managing Director in their life sciences venture practice in 2001. From 1999 to 2001, Dr. Ferguson was a partner at InterWest Partners, a venture capital firm. Prior to InterWest, he held a variety of management positions over an 11-year career at Genentech, Inc., most recently as Senior Director of Business and Corporate Development responsible for worldwide licensing transactions for both technology and pharmaceutical products. Prior to joining Genentech, Inc. in 1988, Dr. Ferguson was an associate with the law firm McCutchen, Doyle, Brown, & Enersen (currently known as Bingham McCutchen llp).

Rod presently serves on the technology advisory board of The Economist, a variety of advisory boards in the life sciences industry, two non-profit boards and several private biotech company boards.

Dr. Ferguson received a B.S. with honors in Biochemistry from the University of Illinois, a PhD in Biochemistry from the State University of New York at Buffalo, and a J.D. cum laude from Northwestern University.

Drew Volpe

board of directors

Drew Volpe is the Founding Partner at First Star Ventures, a venture capital firm that partners with entrepreneurs solving real-world problems using data and machine learning, focusing on applications of frontier technologies such as AI, computational biotechnology, and blockchain.

Drew is an accomplished investor, entrepreneur, and technologist with a deep experience in the technologies he funds. Prior to founding First Star Ventures, Drew was the founding VP of Product Development for conversational AI startup Semantic Machines. He was Co-Founder and CTO of Locately where he led development of Locately's location-based market research platform from inception through the company's successful acquisition by SMG. Prior to Locately, Drew was Director of Product Development at Endeca Technologies, a pioneer in search and unstructured database systems, acquired by Oracle for $1.1 billion.

Drew holds an AB in Computer Science from Harvard University.

Rachael Craig

co-founder and ceo

Rachael Craig is the visionary behind MotionHall where she engages directly with the membership base, and has pioneered the development of modern best practices for building biopharmaceutical company value.

Rachael founded MotionHall in 2015 with the belief that expertly applied Artificial Intelligence (AI) to mass amounts life sciences industry data would empower industry dealmakers to work with unprecedented market transparency, empowering the way they manage building company value, informing everything from portfolio investment decisions to complex multi-stakeholder transactions.

Rachael has led MotionHall from conception through venture financing to a global Platform membership base serving biotech and pharmaceutical company leaders in every major pharmaceutical region as well as LATAM and MENA. She has developed MotionHall's Strategy Consulting team to deliver flexible, expert and advanced services for biopharma companies who wish to better leverage MotionHall's Model, Platform and Method in their work.

Prior to MotionHall, Rachael led a hybridized career across life sciences, business and frontier software as an independent consultant and advisor in biotechnology, entrepreneurship and economic development, industry software, startups and blockchain.

She leads a mission-driven life and cares deeply about accelerating science to market, where it can help people.

Rachael has a B.S. in Neuroscience from Dalhousie University focused on computational research methods.

Method and Strategic Advisory Team

Rachael Craig

co-founder and ceo

Rachael Craig is the visionary behind MotionHall where she engages directly with the membership base, and has pioneered the development of modern best practices for building biopharmaceutical company value.

Rachael founded MotionHall in 2016 with the belief that expertly applied Artificial Intelligence (AI) to mass amounts life sciences industry data would empower industry dealmakers to work with unprecedented market transparency, empowering the way they manage building company value, informing everything from portfolio investment decisions to complex multi-stakeholder transactions.

Rachael has led MotionHall from conception through venture financing to a global Platform membership base serving biotech and pharmaceutical company leaders in every major pharmaceutical region as well as LATAM and MENA. She has developed MotionHall's Strategy Consulting team to deliver flexible, expert and advanced services for biopharma companies who wish to better leverage MotionHall's Model, Platform and Method in their work.

Prior to MotionHall, Rachael led a hybridized career across life sciences, business and frontier software as an independent consultant and advisor in biotechnology, entrepreneurship and economic development, industry software, startups and blockchain.

She leads a mission-driven life and cares deeply about accelerating science to market, where it can help people.

Rachael has a B.S. in Neuroscience from Dalhousie University focused on computational research methods.

Ali Spindt

Associate Consultant

Ali Spindt, Associate Consultant is based in Menlo Park, CA, and provides strategy consulting support to MotionHall companies across all sectors and geographies in biopharma.

Prior to MotionHall, Ali helped found Santa Barbara Nutrients (SBN), a company focused on natural products for treating kidney disease alongside her graduate school advisor. Ali supported SBN from ideation through Series A financing. Prior to SBN, Ali worked as an analyst at Longitude Capital evaluating healthcare company leadership, technology and financials for venture investment.

Ali graduated UC Santa Barbara with a Masters degree in Molecular, Cellular and Development Biology with an emphasis in Biotechnology and Pharmacology.

Jamie Graham

Director of Member Services

Jamie Graham leads Member Services at MotionHall, ensuring that all of MotionHall members receive appropriate and timely support towards accomplishing their company goals, inclusive of product support and professional services.

Encompassing MotionHall's global executive membership, Jamie's book of business includes biotech and pharmaceutical companies working on equity financings, buy- and sell-side M&A, platform and asset licensing partnerships, indication prioritization and portfolio optimization, market tracking and more.

Jamie brings over 15 years experience in financial, investment and client services where she has been recognized for her ability to build trusted relationships and to provide digestible consultative guidance addressing both current and future needs.

Jamie's credentials and designations include a BA in Economics with Honors, and numerous designations in wealth management, securities compliance, conduct and best practices. She holds an affiliation with the Investment Industry Regulatory Organization of Canada (IIROC).

Danielle Lovell

SVP Relationship Intelligence

Danielle Lovell is SVP Relationship Intelligence at MotionHall and part of the company founding team. Danielle has personally architected and oversees MotionHall's relationship and people-based partnering intelligence team and software infrastructure.

Playing a powerful behind-the-scenes role in global transactions, Danielle sits on a daily basis at the intersection of communications between critical stakeholders at biotech and pharmaceutical companies worldwide. By focusing on placing clients at the forefront of critical communications, dealmakers may not know Danielle, but she knows them. Companies who have the benefit of working with Danielle and her team will accrue the required relationship capital to drive immediate transaction goals forward, as well as retain these relationships to support long-term alliances.

Prior to accepting her role as SVP Relationship Intelligence, Danielle honed her abilities in high-touch industry relationships managing them with innovative software-driven solutions as Chief of Staff to our CEO, Rachael Craig.

Danielle has led in multiple entrepreneurial and early-growth stage roles in frontier technology and technology-enabled companies including Hootsuite, Blankslate Partners, Over the Moon Games, and Lululemon.

Danielle graduated Yale University in 2006 with a Bachelor's Degree in Psychology.

Matt Jewkes

co-founder and cto

Matthew Jewkes has led at the forefront of multiple significant transitions in software, from introduction of the iPhone to advanced cryptographic methods, and now the rapidly emerging capabilities of Artificial Intelligence (AI) technologies.

Matthew oversees the development of MotionHall's technology, including the Model and Platform. Since inception in 2015, Matt has guided the development of a comprehensive digital twin of the global biopharmaceutical industry known as the MotionHall Model. This model leverages terabytes of proprietary industry data, massively indexed public data sets, and works on proprietary deep learning neural networks as well as other computational methodologies.

Matthew is also responsible for the creation and development of the Platform, including the specific deal enablement workflows and decision support tools available to MotionHall's membership.

Matt is an advocate for corporate social responsibility, customer success and employee success. Within MotionHall, he is a champion for the benefit of our members and the patients they serve. He has taken a strong stand against non-compete agreements which restrict employees' basic freedom to change jobs, and lead in equity education and options terms that protect teammates including a 10-year exercise period.

Matt studied Computer Science at Dalhousie University.

Derek Rodgers

Director of Quality

Delivering best-in-class results at MotionHall are a hybridization of expert people and machines. As Director of Quality, Derek leads as a hybrid specialist at the interface point between MotionHall's Model and Platform to ensure that customer requirements are fully modeled with accuracy and quality assurance.

Prior to MotionHall, Derek worked developing software-based training simulations for government clients. He graduated BSc with Honors in Neuroscience from Dalhousie University.

Derek's dual background in neuroscience and software development allows him to ensure quality in all customer deliverables to the Platform.

We believe in the power of small teams to
achieve great things.

Leveraged on top of technology, teammates at MotionHall work to maintain a team as small and high-powered as possible so that we can assure quality and agility in results for our membership.

Our small but powerful team is comprised of just 30 teammates spanning every major pharmaceutical geography.

From inception in 2016, MotionHall has been supported by many of the world's most successful pharmaceutical and technology industry veterans, including senior advisors from Genentech, Veeva, and Palantir.

We are a venture backed Silicon Valley technology company supported by Village Global, a network-driven fund backed by Bill Gates, Michael Bloomberg and Jeff Bezos, as well as First Star Ventures and Outlier Ventures.

Our frontier engineering team consists of respected engineering leaders in high-demand, and who prefer to serve preferred outcomes for patients through MotionHall. They include the experts behind Signal iOS 1.0, as well as the Rust-Axolotl Double Ratchet Cryptography implementation (Diffie-Hellman × Symmetric Ratchet over Curve25519 / AES-256). In collaboration with our domain experts, this team has developed MotionHall's Model which includes multiple custom, domain specific Artificial Intelligence (AI) models including classification, prediction, regression and other computational methods, as well as our own proprietary multi-terabyte labeled dataset.